Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. (Q50998286)
Jump to navigation
Jump to search
scientific article published on 8 December 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. |
scientific article published on 8 December 2014 |
Statements
Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemia. (English)
1 reference
1 reference
E Raffoux
1 reference
N Boissel
1 reference
A L Andreoli
1 reference
P Rousselot
1 reference
H Dombret
1 reference
E Messas
1 reference
8 December 2014
1 reference
1 reference
29
1 reference
5
1 reference
1206-1209
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference